Topiramate for the treatment of epilepsy and other nervous system disorders

References

• Begley CE, Famulari M, Annegers JF et al. The cost of epilepsy in the US: an estimate from population-based clinical and survey data. Epilepsia 41(3), 342–351 (2000).
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Dichter MA. Anti-epileptic drugs. N. Engl. J. Med. 334, 168–175 (1996).
   PubMed Web of Science ®Google Scholar
• Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia 34, 453–468 (1993).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed, M. Prevalence and burden of migraine in the US: data from the American migraine study II. Headache 41, 646–657 (2001).
   PubMed Web of Science ®Google Scholar
• Maryanoff BE, Nortey SO, Gardocki JF, Shank RP, Dodgson SP. Anticonvulsant O-alkyl sulfamates. 2,3, 4,5-bis-O(1-methylethylidene)-β-D-fructopyranose sulfamate and related compounds. J. Med. Chem. 30(5), 880–887 (1987).
   PubMed Web of Science ®Google Scholar
• Reismuller E, Ebert U, Loscher W. Anticonvulsant efficacy of topiramate in phenytoin-resistant kindled rats. Epilepsia 41(4), 372–379 (2000).
   PubMedGoogle Scholar
• Edmonds HL Jr, Jiang YD, Zhang PY, Shank RP. Anticonvulsant activity of topiramate and phenytoin in a rat model of ischaemia-induced epilepsy. Life Sci. 59(10), 127–131 (1996).
   Web of Science ®Google Scholar
• Borowicz KK, Luszczki JJ, Duda AM, Czuczwar SJ. Effect of topiramate on the anticonvulsant activity of conventional anti-epileptic drugs in two models of experimental epilepsy. Epilepsia 44(5), 640–646 (2003).
   PubMed Web of Science ®Google Scholar
• Nakamura J, Tamura S, Kanda T et al. Inhibition by topiramate of seizures in spontaneously epileptic rats and DBA/2 mice. Eur. J. Pharmacol. 254(1–2), 83–89 (1994).
   PubMed Web of Science ®Google Scholar
• Rigoulot MA, Boehrer A, Nehlig A. Effects of topiramate in two models of genetically determined generalized epilepsy, the GAERS and the audiogenic wistar AS. Epilepsia 44(1), 14–19 (2003).
   PubMedGoogle Scholar
• Zona C, Ciotti MT, Avoli M. Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells. Neurosci Lett. 231(3), 123–126 (1997).
   PubMed Web of Science ®Google Scholar
• Kuzniecky R, Hetherington H, Ho S et al. Topiramate increases cerebral GABA in healthy humans. Neurology 51(2), 627–629 (1998).
   PubMedGoogle Scholar
• White AS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia 41(Suppl. 1) 17–20, (2000).
   Google Scholar
• Gryder DS, Rogawski MA. Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdale neurons. J. Neurol. Sci. 23, 7069–7074 (2003).
   Google Scholar
• Ängehagen M, Ben-Menachem, E, Shank R, Rönnbäck L, Hansson E. Topiramate modulation of kainite-induced calcium currents is inversely related to channel phosphorylation level. J. Neurochem. 88(2), 320–325 (2004).
   PubMed Web of Science ®Google Scholar
• Herrero AI, Del Olmo N, Gonzalez-Escalada JR, Solis JM. Two new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance. Neuropharmacology 42(2), 210–220 (2002).
   PubMed Web of Science ®Google Scholar
• Storer RJ, Goadsby PJ. Topiramate inhibits trigeminovascular neurons in the cat. Cephalalgia 24(12), 1049–1056 (2004).
   PubMed Web of Science ®Google Scholar
• Silberstein S. Topiramate in migraine prevention. Expert Rev. Neurotherapeutics 3(6), 761–771 (2003).
   PubMedGoogle Scholar
• Easterling DE, Zakszewski T, Moyer MD, Margul BL, Marriott TB, Nayak RK. Plasma pharmacokinetics of topiramate, a new anticonvulsant in humans. Epilepsia 29, 662 (1988).
   Web of Science ®Google Scholar
• Doose DR, Walker SA, Baldassarre J. The effect of food on the oral bioavailability of topiramate from an investigational pediatric sprinkle formulation. Epilepsia 38(Suppl. 3), 147 (1997).
   Google Scholar
• Rosenfeld WE. Topiramate: a review of preclinical, pharmacokinetic, and clinical data. Clin. Ther. 19(6), 1294–1308 (1997).
   PubMed Web of Science ®Google Scholar
• Contin M, Riva R, Albani F, Avoni P, Baruzzi A. Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant anti-epileptic drugs. Ther. Drug Monit. 24(3), 332–337 (2002).
   PubMedGoogle Scholar
• Doose DR, Wang SS, Padmanabhan M, Schwabe S, Jacobs D, Bialer M. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia 44(4), 540–549 (2003).
   PubMed Web of Science ®Google Scholar
• Nallani SC, Glauser TA, Hariparsad N et al. Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate. Epilepsia 44(12), 1521–1528 (2003).
   PubMed Web of Science ®Google Scholar
• Rosenfeld WE, Doose DR, Walker SA, Nayak RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia 38(3), 317–323 (1997).
   PubMed Web of Science ®Google Scholar
• Bialer M, Doose DR, Murthy B et al. Pharmacokinetic interactions of topiramate. Clin. Pharmacokinet. 43(12), 763–780 (2004).
   PubMed Web of Science ®Google Scholar
• Ortho-McNeil, Topamax®, package insert. NJ, USA.
   Google Scholar
• Weintraub D, Buchsbaum R, Resor SR, Hirsch LJ. The effect of anti-epileptic drug co-medication on lamotrigine clearance. Arch. Neurol. 62(9), 1432–1436 (2005).
   PubMed Web of Science ®Google Scholar
• Doose DR, Walker SA, Venkataramanan R, Rabinovitz M, Lever J. Topiramate pharmacokinetics in subjects with liver impairment. Pharm. Res. 11(Suppl.), S446 (1994).
   Google Scholar
• Gisclon LG, Riffitts JM, Sica DA, Gehr T, Ruddley J. The pharmacokinetics (PK) of topiramate (T) in subjects with renal impairment (RI) as compared to matched subjects with normal renal function (NRF). Pharm. Res. 10(Suppl.), S397 (1993).
   Google Scholar
• Gisclon LG, Curtin CR. The pharmacokinetics (PK) of topiramate (T) in subjects with end stage renal disease undergoing hemodialysis. Clin. Pharmacol. Ther. 55, 196 (1994).
   Google Scholar
• Ramsey E, Rowan JA, Spitz,M et al. A double-blind study of topiramate (TPM) monotherapy in older patients with partial-onset seizures. Proceedings of the American Epilepsy Society annual meeting. CA, USA (2004) (Abstract 1.332).
   Google Scholar
• Battino D, Croci D, Rossini A, Messina S, Mamoli D, Perucca E. Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data. Clin. Pharmacokinet. 44(4), 407–416 (2005).
   PubMedGoogle Scholar
• Glauser TA, Miles MV, Tang P, Clark P, McGee K, Doose DR. Topiramate pharmacokinetics in infants. Epilepsia 40(6), 788–791 (1999).
   PubMed Web of Science ®Google Scholar
• Mikaeloff Y, Rey E, Soufflet C et al. Topiramate pharmacokinetics in children with epilepsy aged from 6 months to 4 years. Epilepsia 45(11), 1448–1452 (2004).
   PubMed Web of Science ®Google Scholar
• Kaneko S, Otani K, Fukushima Y et al. Teratogenicity of anti-epileptic drugs: analysis of possible risk factors. Epilepsia 29(4), 459–467 (1988).
   PubMed Web of Science ®Google Scholar
• Montouris G, Creasy G, Khan A, Nero W. Pregnancy outcomes in topiramate-treated women. Epilepsia 44(Suppl. 9), S920 (2003).
   Google Scholar
• Centers for DiseaseControl and Prevention. Use of folic acid for prevention of spina bifida and other neural tube defects: 1983–1991. Morbid. Mortal. Wkly Rep. 40, 513–516 (1991).
   PubMedGoogle Scholar
• Reife R, Pledger G, Wu SC. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia 41(Suppl.1), S66–S71 (2000).
   PubMedGoogle Scholar
• Biton V, Edwards KR, Montouris GD, Sackellares JC, Harden CL, Kamin M. Topiramate-TPS-TR study group. Topiramate titration and tolerability. Ann. Pharmacother. 35(2), 173–179 (2001).
   PubMedGoogle Scholar
• Guberman A, Neto W, Gassmann-Mayer C. The EPAJ-119 study group. Low-dose topiramate in adults with treatment-resistant partial-onset seizures. Acta Neurol. Scand. 106, 183–189 (2002).
   PubMed Web of Science ®Google Scholar
• Gilliam FG, Veloso F, Bomhof MA et al. A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Neurology 60(2), 196–202 (2003).
   PubMed Web of Science ®Google Scholar
• Wheless JW, Neto W, Wang S. EPMN-105 study group. Topiramate, carbamazepine, and valproate monotherapy: double-blind comparison in children with newly diagnosed epilepsy. J. Child Neurol. 19(2), 135–141 (2004).
   PubMed Web of Science ®Google Scholar
• Biton V, Montouris GD, Ritter F et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC study group. Neurology 52(7), 1330–1337 (1999). 53(5), 1162 (1999) (Erratum).
   PubMed Web of Science ®Google Scholar
• Chadwick D, Leiderman DB, Sauermann W, Alexander J, Garofalo E. Gabapentin in generalized seizures. Epilepsy Res. 25(3), 191–197 (1996).
   PubMed Web of Science ®Google Scholar
• Beran RG, Berkovic SF, Dunagan FM et al. Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalized epilepsy. Epilepsia 39(12), 1329–1333 (1998).
   PubMed Web of Science ®Google Scholar
• Glauser TA, Clark PO, Strtawsburg R. A pilot study of topiramate in the treatment of infantile spasms. Epilepsia 39(12), 1324–1328 (1998).
   PubMed Web of Science ®Google Scholar
• Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G. A double-blind, randomized trial of topiramate in lennox–gastaut syndrome. Topiramate YL study group. Neurology 52(9), 1882–1887 (1999).
   PubMed Web of Science ®Google Scholar
• Glauser TA, Levisohn PM, Ritter F, Sachdeo RC. Topiramate in Lennox–Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Topiramate YL study group. Epilepsia 41(Suppl. 1), S86–S90 (2000).
   PubMedGoogle Scholar
• Silberstein SD, Schmitt J, Neto W, Jacobs D. MIGR-001 study group. Topiramate in migraine prevention: results of a large controlled trial. Arch. Neurol. 61(4), 490–495 (2004).
   PubMed Web of Science ®Google Scholar
• Brandes JL, Saper JR, Diamond M et al. The MIGR-002 study group. Topiramate for migraine prevention: a randomized controlled trial. JAMA 291(8), 965–973 (2004).
   PubMed Web of Science ®Google Scholar
• Diener HC, Tfelt-Hansen P, Dahlof C et al. MIGR-003 study group. Topiramate in migraine prophylaxis-results from a placebo-controlled trial with propranolol as an active control. J. Neurol. 251(8), 943–950 (2004).
   PubMed Web of Science ®Google Scholar
• Knowler WC, Barrett-Connor E, Fowler SE et al. Diabetes prevention program research group. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346(6), 393–403 (2002).
   PubMed Web of Science ®Google Scholar
• Bray GA, Hollander P, Klein S et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes. Res. 11(6), 722–733 (2003).
   PubMedGoogle Scholar
• Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M. Obes-002 study group. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int. J. Obes. Relat. Metab. Disord. 28(11), 1399–1410 (2004).
   PubMed Web of Science ®Google Scholar
• Astrup A, Caterson I, Zelissen P et al. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes. Res. 12(10), 1658–1669 (2004).
   PubMedGoogle Scholar
• Zvartau-Hind M, Din MU, Gilani A et al. Topiramate relieves refractory trigeminal neuralgia in MS patients. Neurology 55, 1587–1588 (2000).
   PubMedGoogle Scholar
• Solaro C, Uccelli MM, Brichetto G, Gaspperini C, Mancardi G. Topiramate relieves idiopathic and symptomatic trigeminal neuralgia. J. Pain Symptom Manage. 21(5), 367–368 (2001).
   PubMed Web of Science ®Google Scholar
• Durand JP, Alexandre J, Guillevin L, Goldwasser F. Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy. AntiCancer Drugs 16(5), 587–591 (2005).
   PubMedGoogle Scholar
• Thienel U, Neto W, Schwabe SK, Vijapurkar U. Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials. Acta Neurol. Scand. 110(4), 221–231(2004).
   PubMed Web of Science ®Google Scholar
• Calabrese JR. A placebo-controlled study of topiramate in acute mania. European College of Neuropsychopharmacology Annual Meeting. Munich, Germany (2000).
   Google Scholar
• Toalson P, Ahmed S, Hardy T, Kabinoff G. The metabolic syndrome in patients with severe mental illnesses. Prim. care companion. J. Clin. Psych. 6(4), 152–158 (2004).
   Google Scholar
• Jobe PC. Affective disorder and epilepsy comorbidity: implications for development of treatments, preventions and diagnostic approaches. Clin. EEG Neurosci. 35(1), 53–68 (2004).
   PubMedGoogle Scholar
• Vetulani J. Drug addiction. Part II. Neurobiology of addiction. Pol. J. Pharmacol. 53(4), 303–317 (2001).
   PubMedGoogle Scholar
• Spanagel R. The role of the glutamatergic system in alcohol addiction. Fortschr. Neurol. Psychiatr. 71(Suppl. 1), S33–S35 (2003).
   PubMedGoogle Scholar
• Dodd PR, Beckmann AM, Davidson MS, Wilce PA. Glutamate-mediated transmission, alcohol and alcoholism. Neurochem. Int. 37, 509–533 (2000).
   PubMedGoogle Scholar
• Johnson BA, Ait-Daoud N, Bowden CL et al. Oral topiramate for treatment of alcohol dependence: a randomized controlled trial. Lancet 361(9370), 1677–1685 (2003).
   PubMed Web of Science ®Google Scholar
• Kampman KM, Pettinati H, Lynch KG et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend. 75(3), 233–240 (2004).
   PubMed Web of Science ®Google Scholar
• Yang Y, Shuaib A, Li Q, Siddiqui MM. Neuroprotection by delayed administration of topiramate in a rat model of middle cerebral artery embolization. Brain Res. 804(2), 169–176 (1998).
   PubMed Web of Science ®Google Scholar
• Rigoulot MA, Koning E, Ferrandon A, Nehlig A. Neuroprotective properties of topiramate in the lithium–pilocarpine model of epilepsy. J. Pharmacol. Exp. Ther. 308(2), 787–795 (2004).
   PubMed Web of Science ®Google Scholar
• Kudin AP, Debska-Vielhaber G, Vielhaber S, Elger CE, Kunz WS. The mechanism of neuroprotection by topiramate in an animal model of epilepsy. Epilepsia 45(12), 1478–1487 (2004).
   PubMed Web of Science ®Google Scholar
• Koh S, Jensen FE. Topiramate blocks perinatal hypoxia-induced seizures in rat pups. Ann. Neurol. 50(3), 366–372 (2001).
   PubMedGoogle Scholar
• Koh S, Tibayan FD, Simpson JN, Jensen FE. NBQX or topiramate treatment after perinatal hypoxia-induced seizures prevents later increases in seizure-induced neuronal injury. Epilepsia 45(6), 569–575 (2004).
   PubMedGoogle Scholar
• Hamm LL. Renal handling of citrate. Kidney Int. 38, 728–735 (1999).
   Google Scholar
• Lamb EJ, Stevens PE, Nashef L. Topiramate increases biochemical risk of nephrolithiasis. Ann. Clin. Biochem. 41(Pt 2), 166–169 (2004).
   PubMed Web of Science ®Google Scholar
• Sankar PS, Pasquale LR, Grosskreutz CL. Uveal effusion and secondary angle-closure glaucoma associated with topiramate use. Arch. Ophthalmol. 119(8), 1210–1211 (2001).
   PubMed Web of Science ®Google Scholar
• Craig JE, Ong TJ, Louis DL, Wells JM. Mechanism of Topiramate-induced acute-onset myopia and angle closure glaucoma. Am. J. Ophthalmol 137(1), 193–195 (2004).
   PubMed Web of Science ®Google Scholar
• Ko CH, Kong CK. Topiramate induces metabolic acidosis: report of two cases. Dev. Med. Child Neurol. 43, 701–704 (2001).
   PubMed Web of Science ®Google Scholar
• Philippi H, Boor R, Reitter B. Topiramate and metabolic acidosis in infants and toddlers. Epilepsia 43(7), 744–747 (2002).
   PubMed Web of Science ®Google Scholar
• Martin R, Kuzniecky R, Ho S et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 52(2), 321–327 (1999).
   PubMed Web of Science ®Google Scholar
• Meador KJ, Loring DW, Hulihan JF, Kamin M, Karim R, CAPSS-027 study group. Differential cognitive and behavioral effects of topiramate and valproate. Neurology 60(9), 1483–1488 (2003).
   PubMed Web of Science ®Google Scholar
• Meador KJ, Loring DW, Vahle VJ et al. Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers. Neurology 64(12), 2108–2114 (2005).
   PubMed Web of Science ®Google Scholar
• Salinsky MC, Storzbach D, Spencer DC, Oken BS, Landry T, Dodrill CB. Effects of topiramate and gabapentin on cognitive abilities in healthy volunteers. Neurology 64(5), 792–798 (2005).
   PubMed Web of Science ®Google Scholar
• Mula M, Trimble MR, Thimpson P, Sander JW. Topiramate and word-finding difficulties in patients with epilepsy. Neurology 60(7), 1104–1107 (2003).
   PubMed Web of Science ®Google Scholar
• Storey JR, Calder CS, Hart DE, Potter DL. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 41(10), 968–975 (2001).
   PubMed Web of Science ®Google Scholar
• Martinez HR, Londono O, Cantu-Martinez L, del Carmen Tarin L, Castillo CD. Topiramate as an adjunctive treatment in migraine prophylaxis. Headache 43(10), 1080–1084 (2003).
   PubMed Web of Science ®Google Scholar
• Von Seggern RL, Mannix LK, Adelman JU. Efficacy of topiramate in migraine prophylaxis: a retrospective chart analysis. Headache 42(8), 804–809 (2002).
   PubMedGoogle Scholar
• Edwards KR, Potter DL, Wu SC, Kamin M, Hulihan J. Topiramate in the preventive treatment of episodic migraine: a combined analysis from pilot, double-blind, placebo-controlled trials. CNS Spectr. 8(6), 428–432 (2003).
   PubMed Web of Science ®Google Scholar
• Mei D, Capuano A, Vollono C et al. Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study. Neuro. Sci. 25(5), 245–250 (2004).
   PubMed Web of Science ®Google Scholar
• Lainez MJ, Pascual J, Pascual AM, Santonja JM, Ponz A, Salvador A. Topiramate in the prophylactic treatment of cluster headache. Headache 43(7), 784–789 (2003).
   PubMed Web of Science ®Google Scholar
• Mathew NT, Kailasam J, Meadors L. Prophylaxis of migraine, transformed migraine, and cluster headache with topiramate. Headache 42(8), 796–803 (2002).
   PubMed Web of Science ®Google Scholar
• Stephen LJ, Sills GJ, Brodie MJ. Topiramate in refractory epilepsy: a prospective observational study. Epilepsia 41(8), 977–980 (2000).
   PubMed Web of Science ®Google Scholar
• Guerrini R, Carpay J, Groselj J et al., on behalf of the TOP-INT-51 investigators’ group. Topiramate monotherapy as broad spectrum anti-epileptic drug in a naturalistic clinical setting. Seizure (2005) (Epub ahead of print).
   PubMedGoogle Scholar
• Privitera MD, Brodie MJ, Mattson RH, Chadwick DW, Neto W, Wang S. EPMN 105 study group. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol. Scand. 107(3), 165–175 (2003).
   PubMed Web of Science ®Google Scholar
• Weintraub D, Hirsch LJ, Buchsbaum R, Resor SR Jr. Tolerability of topiramate in 342 patients: analysis by dose and serum concentration. Epilepsia 45(Suppl. 7), S137 (2004).
   Google Scholar
• Weintraub D, Buchsbaum R, Spencer HT et al. Cognitive side effects of the newer anti-epileptic drugs: results from the Columbia anti-epileptic drug database. Neurology 62(Suppl. 5), A311 (2004).
   Google Scholar
• Weintraub D, Buchsbaum R, Spencer HT et al. Psychiatric side effects of the newer anti-epileptic drugs: results from the columbia anti-epileptic drug database. Neurology 62(Suppl.5), A309 (2004).
   Google Scholar
• Weintraub D, Resor SR, Bazil CW, Hirsch LJ. Head to head comparison of the sedating effect of anti-epileptic drugs in adults with epilepsy: results from the Columbia anti-epileptic drug database. Neurology 64(Suppl. 1), A114 (2005).
   PubMedGoogle Scholar
• Salas-Humara C, Weintraub D, Buchsbaum R et al. Comparative incidence of rash related to twelve anti-epileptic drugs: results from the Columbia anti-epileptic drug database. Neurology 6 (Suppl. 5), A352 (2004).
   Google Scholar
• Cantero J, Weintraub D, Buchsbaum R, Hirsch LJ. Cosmetic side effects of the anti-epileptic drugs. Epilepsia 45(Suppl. 7), S306–S307 (004).
   Google Scholar
• Naritoku DK, Hulihan JF, Schwarzman LK, Kamin M, Olson WH. Effect of cotherapy reduction on tolerability of epilepsy add-on therapy: a randomized controlled trial. Ann. Pharmacother. 39(3), 418–423 (2005).
   PubMedGoogle Scholar